Heinz Lubenau

Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

Henogen SA develops and manufactures biopharmaceuticals. The company was founded on November 19, 1999 and is headquartered in Charleroi, Belgium.

Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland.

Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

The European Vaccine Initiative manufactures vaccines. The private company is based in London, UK.

Messier Maris & Associés SCA provides financial consulting and investment advisory services. The company was founded by Jean-Marie Messier and Erik Maris in 2010 and is headquartered in Paris, France.

develops vaccines to cure disorders of the immune system. Its services include preclinical evaluation, clinical immunomonitoring, technical transfer, consulting and training services, cell, gene, and protein readout development, and clinical biomarker panels validation. The company was founded in 2007 and is headquartered in Gosselies, Belgium.

Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium.

20Med Therapeutics BV operates as a biomedical company. It focuses on the development of biodegradable materials for biomedical applications and multifunctional nanosystems for controlled drug and gene delivery. The company was founded by Johan F. J. Engbersen in 2011 and is headquartered in Enschede, the Netherlands.

4 for Cells SPRL provides business outsourcing services. The private company is based in Hastière, Belgium. The Belgian company was founded in 2011. François Lesage has been the CEO of the company since 2011.

MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium.

Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium.

Aileens Pharma Srl is a holding company, which engages in the research and development of treatments for dermatological diseases. The company was founded by Sonia Longo Sormani in 2018 and is headquartered in Nova Milanese, Italy.

Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

OSR Holdings Co., Ltd. is a South Korean healthcare company that develops and licenses innovative biomedical therapies based on proprietary platform technologies to address unmet medical needs. The private company is based in an undisclosed location. The company wholly-owns three operating subsidiaries focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases. OSR Holdings signed a letter of intent to acquire Landmark Bioventures AG, a Swiss company that operates through four different biotech ventures with therapeutic focuses on oncology and immunology. The company was founded in 2019, and the CEO is Sean Chung.

Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy.

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.

DNAlytics SA engages in the development of data-driven precision medicine solutions. The firm provides consultancy services; and academic medical, biological, and clinical research laboratories for the pharmaceutical, biotechnology and In-Vitro Diagnostic companies. It also offers software programs unde rthe REED, LiblineaR, jForest, and BLISS brands. The company was founded by Pierre Dupont and Thibault Helleputte in 2012 and is headquartered in Louvain-la-Neuve, Belgium.